Appili Therapeutics Inc. APLIF
0.00 USD 0.00 (+0.00%)
At closeNov 11, 2026, 4:00 PM EST
0.004 Day range 0.0068
0.002 52-week range 0.02
- YTD
- -86.67%
- 1 year
- -87.50%
News
newsfilecorp.com Appili Therapeutics Announces Transfer to NEX Halifax, Nova Scotia--(Newsfile Corp. - September 29, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug…
newsfilecorp.com Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027 Appili adopts a new business strategy that focuses on the biodefence sector Halifax, Nova Scotia--(Newsfile Corp. - August 14, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the…
globenewswire.com Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for…
globenewswire.com Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1
globenewswire.com Appili Therapeutics to Exhibit at World Vaccine Congress Washington Appili Presentation Highlights Recent Collaborations and Funding Milestones Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities HALIFAX, Nova…
globenewswire.com Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the…
globenewswire.com Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026 US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase 1 LIKMEZ® (ATI-1501) Commercial Momentum…
globenewswire.com Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026 New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs
globenewswire.com Appili Therapeutics to Attend BARDA Innovation Symposium 2025 Highlights Government-Funded Pipeline and Expanding Role of Public-Private Partnerships in Biodefense Innovation Highlights Government-Funded Pipeline and Expanding Role of Public-Private…
globenewswire.com Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01 Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials
globenewswire.com Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for…
globenewswire.com Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026 Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million
globenewswire.com Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine Peer-reviewed publication highlights ATI-1701's robust protection against aerosolized Francisella tularensis exposure in multiple animal models
globenewswire.com Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia,…
globenewswire.com Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:…
globenewswire.com Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:…
globenewswire.com Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia A review of recent findings suggests that Appili's biodefense vaccine, ATI-1701, may have a role in preventing tularemia outbreaks A review of recent findings suggests that Appili's biodefense…
globenewswire.com Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™ New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ
globenewswire.com Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025 Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE…
globenewswire.com Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update Four new funding proposals, totalling US$117.5 million, have been submitted for review Modifications received to U.S. Air Force Academy Cooperative Agreement Outside date for going-private…